B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy

CD4 T cell dependent rejection of beta 2 microglobulin null mismatch repair deficient tumors

(2021) Giovanni Germano et al.   Cancer Discovery

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

(2021) Karthik Dhatchinamoorthy et al.   Frontiers in Immunology

Overcoming genetically-based resistance mechanisms to PD-1 blockade

(2020) Davis Y. Torrejon et al.   Cancer Discovery

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients

(2020) Peng Song et al.   Thoracic Cancer

Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer

(2020) Binyi Xiao et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature

(2020) Lennox Chitsike et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

(2019) Saori Mishima et al.   Journal for ImmunoTherapy of Cancer

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer

(2019) André F. Oliveira et al.   Frontiers in Oncology

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

(2019) Joseph L. Benci et al.   CELL

Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer

(2019) Zuzana Snahnicanova et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features

(2018) Wu Jiang et al.   INTERNATIONAL JOURNAL OF CANCER

Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma

(2018) Su Yeon Yeon et al.   PATHOLOGY RESEARCH AND PRACTICE

PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer

(2017) Francesco Sclafani   LANCET ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

JAK Mutations as Escape Mechanisms to Anti–PD-1 Therapy

(2017) Aurelien Marabelle et al.   Cancer Discovery

High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer

(2017) Jonas Janikovits et al.   OncoImmunology

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

EGFRgene copy number predicts response to anti-EGFR treatment inRASwild type andRAS/BRAF/PIK3CAwild type metastatic colorectal cancer

(2016) Annika Ålgars et al.   INTERNATIONAL JOURNAL OF CANCER

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

β2-Microglobulin deficiency causes a complex immunodeficiency of the innate and adaptive immune system

(2015) Ömür Ardeniz et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE